Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 in Esophageal Squamous Cell Carcinoma
NCT01806649Phase 2Terminated
- Sponsor
- Prince of Songkla University
- Start
- Jul 2013
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of buparlisib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Prince of Songkla University. Primary endpoint: Disease Control Rate at 16 weeks. Started Jul 2013; status: terminated.
02
Drugs
buparlisib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT01806649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01806649.